Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
HIF-2 alpha/EPAS1 Antibody (ep190b), DyLight 405, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB100132V
Description
HIF-2 alpha/EPAS1 Monoclonal specifically detects HIF-2 alpha/EPAS1 in Human, Mouse, Rat, Bovine, Hamster samples. It is validated for Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Knockdown Validated.Specifications
HIF-2 alpha/EPAS1 | |
Monoclonal | |
DyLight 405 | |
Q99814 | |
EPAS1 | |
The immunogen recognized by this HIF-2 alpha/EPAS1 Antibody (ep190b) maps to a region between amino acids 535-631. [UniProt# Q99814] | |
Protein G purified | |
RUO | |
Primary | |
This HIF-2 alpha/EPAS1 Antibody (ep190b) is specific for HIF-2 alpha/EPAS1, and does not cross-react with HIF-1 alpha. | |
Store at 4C in the dark. | |
IgG1 |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), KnockDown | |
ep190b | |
Western Blot, Flow Cytometry, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Knockdown Validated | |
Basic-helix-loop-helix-PAS protein MOP2, BHLHE73, Class E basic helix-loop-helix protein 73, ECYT4, endothelial PAS domain protein 1, endothelial PAS domain-containing protein 1, EPAS1, EPAS-1, HIF-1-alpha-like factor, HIF-1alpha-like factor, HIF-2 alpha, | |
Mouse | |
118 kDa | |
0.1 mL | |
Angiogenesis, Apoptosis, Cancer, Cancer Stem Cells, Chromatin Research, Embryonic Stem Cell Markers, HIF Target Genes, Hypoxia, Lipid and Metabolism, Transcription Factors and Regulators | |
2034 | |
Human, Mouse, Rat, Bovine, Hamster | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction